Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Within the Italian CNR Biomedical Technology programmes a large multicentre clinical trial on CEA-expressing carcinomas has been carried out. F(ab')2 fragments of anti-CEA monoclonal antibody (MAb) FO23C5, radiolabelled with either 131I or 111In, were supplied to 10 different Italian nuclear medicine departments. Over 500 patients with gastrointestinal, lung, breast, and other carcinomas have been investigated. The results obtained in our nuclear medicine department are reported here. In GI cancer group, the 131I compound showed better results except in liver metastases detected only in 28/57 patients. In the lung cancer group, very satisfactory results were achieved in primary tumours and local or systemic recurrences: 111In tracer was preferentially used. In the breast cancer group immunoscintigraphy proved to be helpful in differential diagnosis of neoplastic and benign bone lesions. Significant improvements of diagnostic sensitivity were achieved in GI cancer patients by means of i.p. administration. Finally, 12 patients with advanced disease were given different 131I radioiodinated MAbs (100 mCi average dose). Administration route was either i.v. (3 cases) or i.p. (9 cases). Clinical and instrumental evidence of complete (1) or partial (7) response was observed in 8 patients.
 ...
PMID:Antibody-guided diagnosis: an Italian experience on CEA-expressing tumours. 316 39

There is not as yet a specific marker for lung cancer. We tested the specificity of six serum markers using radio-immunological assays (CA-50, CA-19.9, CA-125, CA-15.3, Enolase, CEA) in 60 patients with non-neoplastic diseases of the lung (COPD: 28 patients, acute pneumonia: 23 patients, allery: 9 patients). No correlation was found between the percentage of false positivities on the one hand, and sex, age and smoking habits on the other. CA-125 proved to be positive in 74% of acute pneumonia cases. The rate of false positive values is low with CEA (3.3%), Enolase (6.7%) and CA-15.3 (5%) and therefore the cut-off value we chose for these markers was adequate. This is not the case with CA-50, CA-19.9 and CA-125, for which we observed a high rate of false positive values (33.3%, 13.3% and 53.3% respectively) and for which higher cut-off values must be adopted.
 ...
PMID:Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung. 317 58

The CA 50 levels in serum samples from 440 patients were estimated using a dissociated enhanced lanthanide immunofluorimetric assay. The distribution was similar to CA 50-RIA assays. Raised levels (greater than 14 U/ml) were present in 95% pancreatic cancer, 68% hepatoma, 54% advanced colorectal cancer, 58% advanced breast cancer and 48% lung cancer. High values were observed in adenocarcinoma of the lung, and were related to tumour mass in small cell lung cancer. CA 50 is independent of CEA. The marker is of considerable potential in pancreatic cancer where the majority of patients express the Can 50 Ag.
 ...
PMID:An evaluation of serum CA 50 levels in cancer using a time-resolved fluoroimmunoassay. 317 5

The value of CEA and Ca 19-9 assays in the diagnosis and staging of lung cancer is examined. The particular sensitivity of CEA especially in extensive or metastasised tumours is demonstrated. The minimal sensitivity of Ca 19-9 is pointed out but also its absolute specificity in high risk control groups (smokers and BPCO). It is therefore concluded that Ca 19-9 might be used together with CEA in the diagnosis and staging of lung cancer.
 ...
PMID:[Usefulness of the determination of CEA and Ca 19-9 in the diagnosis and staging of bronchial carcinoma]. 347 Jun 32

Twenty patients with lung cancer were treated with a streptococcal preparation, OK-432 in addition to various other treatments, and we evaluated the effect of OK-432 in comparison with an equivalent number of patients without OK-432. With regard to advanced-stage patients, the median survival time of those treated with OK-432 was longer than that of patients without OK-432. Patients whose PPD or SU-PS skin reactions were positive had a longer survival time than those giving a negative reaction. OK-432 significantly increased the reactions for both PPD and SU-PS. On the other hand, OK-432 did not have any significant effect in increasing the numbers of peripheral lymphocytes and T-cell subsets. Furthermore, there were no effects on tumor markers, such as CEA, beta 2-microglobulin and ferritin. However, OK-432 had a remarkable effect in decreasing immunosuppressive acidic protein.
 ...
PMID:[The effect of OK-432 in the treatment of primary lung cancer]. 349 30

To establish a model for evaluation of the efficacy and specificity of monoclonal anti-CEA-vindesine (VDS) conjugates, we have characterized 10 human tumor cell lines (7 colorectal cancer and 3 lung cancer) with 3 monoclonal antibodies that recognize different epitopes of the CEA molecule. Immunocytochemistry indicated high, medium, low, or no capacity of the cell lines to bind antibody and express CEA. We used 125I-labeled antibodies to quantitate the number of antibody molecules binding per cell. The most thoroughly evaluated monoclonal antibody, 11-285-14, which is nonreactive with nonspecific cross-reacting antigen and is known to localize in xenografts and in cancer patients, was selected for assessment of VDS-conjugate efficacy. This was evaluated by 24- and 72-hour exposure in tritiated uridine microcytostasis assays with nine of the cell lines. Conjugates were shown to retain anti-CEA activity after conjugation, and the efficacy of VDS-11-285-14 in vitro was found to be correlated with target antigen expression, except with two lines that were resistant to free drug. Absorption of VDS-11-285-14 with purified CEA resulted in loss of efficacy in positive cell lines, thereby giving a further indication of the selectivity of conjugate efficacy.
 ...
PMID:Efficacy and specificity of vindesine monoclonal anti-carcinoembryonic antigen conjugate with nine human cancer cell lines. 354 44

New monoclonal antibodies, CGAD2 and CSLEX1 detected their red cell associated antigens LewisX and sialylated LewisX in serum of cancer patients by reverse passive hemagglutination. With CGAD2, high titers were noted in 56% of the 27 sera from lung adenocarcinoma patients. Of the total 105 sera from cancer patients, 39% showed a positive reaction. With CSLEX1, 48% of the 85 sera from lung adenocarcinoma and 26% of the 384 sera from various cancer patients showed a positive reaction. None of the sera from 80 healthy subjects reacted with this antibody. By testing with these two monoclonal antibodies, 70% of the 46 sera from lung cancer patients showed a positive reaction. Theoretically, LewisX and sialylated LewisX which are type 2 products of the red cell antigen might be more applicable as a tumor marker than type 1 products such as sialylated Lewisa (CA19-9). Furthermore, LewisX could be a tumor marker in some cases whose levels of CEA were comparatively low. These CGAD2 and CSLEX1 monoclonal antibodies should be potentially useful reagents.
 ...
PMID:[Application of monoclonal antibody to detect the red cell associated antigen LewisX and sialylated LewisX in the serum of cancer patient]. 369 35

The auxiliary value of TPA in diagnosing neoplastic diseases was compared to other tumor markers such as CEA, IAP and ferritin. The study population consisted of 59 patients with neoplastic diseases and 75 with benign diseases. The percentages of positive cases for TPA, CEA, IPA and ferritin were 58.9%, 39.0%, 66.7%, and 28.6% in neoplastic diseases and 4.5%, 1.4%, 47.1% and 19.7% in benign diseases, respectively. Both the specificity and sensitivity of TPA were as high as those of CEA. However, the positive rate of TPA was lower than that of CEA in lung cancer patients at stages I and II. TPA was indicated to be a suitable marker for combination assay with CEA in diagnosing neoplastic diseases.
 ...
PMID:[Auxiliary value of TPA in diagnosing neoplastic diseases]. 373 75

A radioimmunoassay was used for a comparative study of CEA concentrations in the blood serum and bronchoalveolar washes-off in patients with lung cancer (27) and nontumorous lung disease (with bronchitis-14, pneumonia-18, tuberculosis-11, disseminated processes of nontumorous etiology.-12) and in persons without lung pathology (7). Diagnostic sensitivity of CEA determination in the washes-off was 89%, in the blood serum 33%; the specificity was 86 and 56.5%, respectively. The resultant diagnostic accuracy using washes-off was 86%, i.e. almost twice as high as compared to the blood serum (44.7%). Such a high accuracy in CEA determination in the bronchoalveolar washes-off provides an opportunity to use the method for differential diagnosis in unclear cases and for defining groups at high risk of developing lung cancer. The combination of a high level of CEA with unfavorable signs like basal cell hyperplasia, epidermoid metaplasia necessitate patients' follow-up.
 ...
PMID:[Carcinoembryonic antigen in bronchoalveolar lavage fluids in the diagnosis of lung cancer]. 378 28

A monoclonal CEA-EIA assay is evaluated with respect to clinically pertinent data. Comparison is done with the conventional CEA-RIA assay (Roche). Good interlaboratory reproducibility was found, and the stability was very good over the one year evaluation period. The EIA assay could be performed in samples of serum and plasma with compatible results. The correlation between the EIA and RIA values was different in different diagnostic groups, with high correlation in colo-rectal cancer, and low in non-malignant diseases, in which the EIA assay had a lower frequency of CEA positive values. In colo-rectal cancer the RIA assay shows a 20% specificity improvement compared with the EIA assay. This was also reflected in better predictability for true positive and true negative cancer diagnosis in this group of patients as well as increased ability to discriminate between malignant and non-malignant diseases. In other groups of patients, like lung cancer and uterine cervical cancer, such improvement was not seen. The discrimination between malignant and non-malignant diseases was comparable to that of the RIA assay. In follow-up series the EIA and RIA assays detected recurrences and responses to treatment in a quite similar way. In most cases of recurrences from colo-rectal cancer, however, the EIA values increased faster and were a better indicator for recurrent disease than the RIA values.
 ...
PMID:Comparison of a CEA-EIA assay based on monoclonal antibody with a CEA-RIA assay with polyclonal antiserum. 390 52


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>